Introduction
Classical features of ulcerative colitis (UC) include chronic relapsing diarrhea, rectal bleeding and inflammation, and abdominal pain, in addition to mucosal ulceration and microscopic crypt abscesses. The areas of mucosal ulceration seen on gross exam of UC specimens demonstrate markedly increased epithelial cell apoptosis and necrosis on histologic examination, both in human UC [1] and in animal models of this disease [2, 3] . Importantly, the epithelial cell apoptotic rate correlates with the severity of the disease [1] . Although the pathophysiology of UC is believed to be multifactorial, the cytokine tumor necrosis factor-α (TNF-α) has been implicated as a critical inflammatory mediator in UC [4] [5] [6] [7] . TNF-α is well established as a major trigger of apoptosis in numerous cell lines [8] , and in addition, the high rate of apoptosis and mucosal injury in UC appears to be mediated by an increase in TNF-α [9, 10] . Therapies that reduce epithelial cell apoptosis and TNF-α levels have led to clinical and histologic improvements in experimental models of colitis [2, 11] .
Recently, angiotensin converting enzyme (ACE) has been shown to play a critical role in apoptosis [19] [20] [21] [22] [23] . ACE is a zinc carboxypeptidase best known for its effects on blood pressure control [24, 25] . Its primary substrate is the decapeptide angiotensin I, which is cleaved by ACE to form the octapeptide angiotensin II (Ang II). ACE inhibition (ACE-I) prevents the formation of Ang II. ACE is expressed at particularly high levels in the pulmonary vascular endothelium, renal tubules, and myocardium, but also-surprisingly-in both the colonic and the small intestinal epithelium [26] [27] [28] . In addition, ACE is shed from the gut epithelium and can be detected in stool [49] . Although the hypertensive effects of Ang II are well known, the function of ACE in the small and large intestine is far less well understood. The effects of ACE and Ang II are mediated through a series of cell surface Ang II receptors; and remarkably, these receptors are also found in the intestinal mucosa-in particular, colonic epithelial cells [26, 29] .
Recent studies demonstrate that ACE is required to initiate apoptosis in a number of tissues, including alveolar epithelial cells and cardiac myocytes [20, [30] [31] [32] . Studies using pharmacologic ACE inhibition (ACE-I) have shown that ACE-I significantly reduces apoptosis in pulmonary and cardiac cells [31] [32] [33] [34] , and this reduction of apoptosis exhibits a concentration-dependent effect [34] . In addition, investigators have shown that Ang II is required for the induction of apoptosis in alveolar epithelial cells and cardiac myocytes [31] [32] [33] [34] [35] [36] . The production of Ang II is precisely what ACE-I prevents. Further studies have strengthened the evidence for the pro-apoptotic effect of ACE. For example, apoptosis induced by Ang II could be completely prevented by Ang II neutralizing antibodies or by an Ang II receptor antagonist [31] . ACE plays a role in apoptosis in a wide variety of tissues, including neural tissues, vascular endothelium, smooth muscle, and fetal adrenals [21, [37] [38] [39] . Interestingly, ACE and Ang II have also been linked to upregulation of TNF-α [40] . In fact, apoptosis attributable to TNF-α was actually shown to be dependent on the binding of Ang II to its receptors on alveolar epithelial cells [8] . TNF-α is therefore probably linked to the pro-apoptotic effects of ACE.
In a model of short bowel syndrome, we found that ACE-I reduces small intestinal epithelial cell apoptosis and reduces the expression of TNF-α as well [22] . But despite the fact that ACE has been found at high levels in colonic epithelium, the effect of ACE-I on colonic epithelial cell apoptosis has not yet been reported. We hypothesized that ACE-I, using enalaprilat, would decrease epithelial cell apoptosis in the dextran sulfate sodium (DSS)-induced colitis model and reduce the severity of UC. Finally, we investigated whether modulation of TNF-α, Bax, and Bcl-2 expression was involved in this action.
Materials and methods

Animals
Specific-pathogen-free male C57BL/6 mice 2-3 months of age (Taconic Farms, Inc., Germantown, NY) were used in accordance with the Guide for the Care and Use of Laboratory Animals [41] and with the approval of the University Committee on Use and Care of Animals at the University of Michigan. In each set of experiments, littermates were randomly assigned to each of the various treatment groups. All animals were kept in the University of Michigan vivarium under temperature-and humidity-controlled conditions with light/dark cycles of 12/12 hr. Animals were fed standard rodent chow ad libitum (LabDiet 5001 Rodent Diet; PMI Nutrition International, LLC, Brentwood, MO).
Colitis model
Colitis was induced by administration of 2.5% (w/v) reagentgrade DSS (MW 36,000-50,000; ICN Biomedicals, Inc., Aurora, OH) dissolved in drinking water provided ad libitum, as described previously [12] [13] [14] [15] [16] [17] .
ACE inhibitor or placebo
Mice were randomly assigned to receive once-per-day intraperitoneal injection of either placebo (normal saline, 0.5 ml) or the ACE inhibitor enalaprilat (Abbott Laboratories, North Chicago, IL; diluted in normal saline solution to a final concentration of 0.03 mg/ml at 14.5 µg per dose = injected volume of 0.5 ml). The treatment (placebo or ACE-I) was administered daily for as many days as the mice were receiving DSS. This dose of enalaprilat was chosen based on previous work in this laboratory that demonstrated a reduction in small intestinal epithelial cell apoptosis with enalaprilat in a model of short bowel syndrome [22] .
Time course of the experiment DSS was administered for either 3 consecutive days followed by euthanasia, 5 days followed by euthanasia, or 7 days plus 1 day returned to plain drinking water, followed by euthanasia. For each series (3, 5, and 7 days of DSS), identical mice from the same lots were randomly assigned to either placebo (n = 6 at each time point) or ACE-I (n = 6 at each time point), as described above.
Besides the placebo and ACE-I groups, two control groups (without DSS) were also used. A "naïve" group (n = 5) received plain drinking water ad libitum and no other treatment. An "ACE-I-only" group (n = 5) received daily intraperitoneal injection of enalaprilat at the same dose as the ACE-I-treated groups (14.5 µg/dose) for a total of 7 days in addition to plain drinking water.
Data and specimen collection
The body weight of each mouse was recorded daily in experimental groups administered DSS for 7 days. Stool was also assessed daily for the presence of occult blood using a guaiaccard test (Cenogenics Stool Blood Test, Cenogenics Corp., Morganville, NJ). After the specified number of days, mice were euthanized with carbon dioxide asphyxiation, and laparotomy with total colectomy was immediately performed. Colons, not including cecum, were placed in RPMI cell culture medium on ice, and fecal contents were gently flushed out. Several 5-to 10-mm sections taken from the distal half of the colon were excised and placed in 10% neutral buffered formalin. Colonic epithelium was isolated for RNA and mucosal protein isolation, as described previously [42] . Briefly, the remainder of the colon was opened longitudinally and rinsed with fresh 4
• C RPMI, then placed mucosal surface up on a glass slide. The epithelium was mechanically scraped off and epithelial cells were collected in fresh RPMI with glutamine on ice. These epithelial cells were then rapidly pelleted in RPMI by centrifugation at 330 × g and 4
• C for 3 min. The supernatant was decanted and the epithelial cell pellet was then immediately snap-frozen in liquid nitrogen and processed for RNA and protein extraction. Sections of colon after epithelial scraping were also examined microscopically, confirming that the mechanical removal of epithelial cells was accurate and did not include submucosa or muscularis.
Assessment of colitis
Formalin-preserved sections of distal colon, as described above, were processed in paraffin with standard technique. Transverse sections 5 µm thick were stained with hematoxylin and eosin (H&E) and were examined independently in duplicate by two observers blinded to the experimental group from which each section came. All grading of colitis was done according to the method described by Cooper et al. [15] . In this method, crypt shortening and distortion, together with inflammatory infiltrative thickening of the lamina propria, are assigned a score of 0 (normal) through 4 (complete loss of crypts, ulceration, and severe thickening of the lamina propria) [15] . The individual scores (0-4) from four different areas of each transverse colonic section were summed, such that the maximum colitis score for a given section is 16, and the minimum score is 0. Several sections were assessed in this manner for each mouse. The final score for each section was the mean of the duplicate independent assessments for that section, and the final histopathologic colitis score for each mouse was therefore the mean of the scores of all the colon sections from that mouse.
Assessment of apoptosis
Tissue sections 5 µm thick from the same regions of colon used to assess colitis severity were stained with the TUNEL (terminal deoxynucleotidyl transferase [TdT] dUTP-nick end labeling) method, using the ApopTag In Situ Peroxidase Cell Death Detection Kit (Serologicals Corporation, Norcross, GA) and a modified technique described previously [43] . Briefly, to prevent false positives, all tissue sections were incubated in 3% H 2 O 2 for 30 min to quench endogenous peroxidases, and TdT enzyme was used at half the supplied concentration to avoid overstaining [43] . A light hematoxylin counterstain was then applied. Specimens were processed simultaneously under identical conditions to guarantee identical staining of slides from different experimental groups. Specimens from the two control groups (naïve and ACE-I-only mice) underwent identical TUNEL staining as well, to determine baseline apoptotic rates. For negative controls (to demonstrate specificity of the TUNEL stain for apoptotic nuclei), parallel samples underwent the same process, but with omission of TdT enzyme. Subsequently, apoptosis was quantified by an observer blinded to the identity of the tissue sections. Independent assessments were performed in duplicate. TUNEL-positive nuclei were clearly identified as brown-stained nuclei, indicating the presence of DNA fragmentation due to apoptosis. TUNEL-positive staining correlated with morphological features of apoptosis (nuclear and cytoplasmic blebbing, chromatin margination) [1, 38, 43] . The apoptotic index was quantified as the number of apoptotic nuclei per crypt, that is, (number of apoptotic nuclei counted)/(number of contiguous colonic crypt units evaluated).
A minimum of 24 colonic crypt units (one crypt plus adjacent surface epithelium) was assessed for every tissue section. The final score for each section was the mean of the independent assessments for that section; the final apoptosis score for each mouse was therefore the mean of the scores of colon sections from that mouse.
Flow cytometry
As an additional assessment of apoptotic rates, epithelial cell surface staining with Annexin V was performed (Annexin V-FITC Apoptosis Detection Kit I; BD Pharmingen, Palo Alto, CA). Propidium iodide was used to distinguish necrotic cells from apoptotic cells, according to the manufacturer's instructions. Annexin V staining was analyzed using flow cytometry (FACSCalibur; Becton Dickinson Immunocytometry Systems, San Jose, CA). Data were analyzed using CELLQuest software (version 3.2.1f1; Becton Dickinson).
RNA isolation
Total epithelial cell RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Purity of RNA was confirmed by spectrophotometric determination of the 260/280 λ absorbance ratio.
Reverse transcription (RT) and polymerase chain reaction (PCR)
Poly(A)-positive mRNA was reverse transcribed into firststrand cDNA using oligo(dT 12−18 ) (Invitrogen) as the primer. All reactions were carried out with the protection of RNAse Inhibitor (Roche, Penzberg, Germany) and RT was performed using Moloney murine leukemia virus (M-MLV) RT (Invitrogen). RT reaction was carried out at 40
• C for 70 min according to a standard protocol [43] . TNF-α, Bcl-2, and Bax expression was quantified using previously validated oligonucleotide primers specific for each mRNA [22] . PCR conditions have been described previously [43] . PCR product was generated at the exponential portion of the product curve. The Kodak EDAS System (Rochester, NY) was used for imaging and quantification of PCR products. All results were normalized to the level of β-actin mRNA expression.
TNF-α mucosal concentration
An enzyme immunometric assay (TiterZyme EIA mouse TNF-α; Assay Designs Inc., Ann Arbor, MI) was used to determine the concentration of TNF-α in the mucosal protein isolate. Samples were performed in duplicate and were standardized to a known concentration of mouse TNF-α (Assay Designs Inc.). Mucosal TNF-α was measured with this technique after 3 and 4 days of DSS, but not later in the course of colitis, due to severe mucosal destruction and mucosal loss later in the course of the disease (see Results, below).
Western blot
The mucosal concentration of ACE protein was assessed using standard Western blot techniques. Briefly, mucosal epithelial cell isolates were homogenized in Nonidet P-40-based (NP-40) buffer at 4
• C. Protein determination was performed using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA). Approximately 60 µg of total protein in loading buffer was loaded per lane in a sodium dodecyl sulfate (SDS)-polyacrylamide gel (13%), and separated using electrophoresis. Proteins were then transferred to a PVDF membrane (Bio-Rad Laboratories). Nonspecific binding to the membrane was controlled with a blocking solution (Zymed Laboratories Inc., USA), and probed with goat anti-mouse biotinylated-ACE Ab (R&D Systems, Inc., Minneapolis, MN; 0.15 µg/ml in blocking solution) for 1 hr. Bound antibodies were exposed to a strepavidin-horseradish peroxidase (HRP) conjugate (1:10,000; Zymed Laboratories Inc.), detected on x-ray film, and quantified using Kodak 1D image quantification software (Kodak Co., Rochester, NY).
Mucosal and mesenteric blood flow
To evaluate the effects of administration of ACE-I on mesenteric as well as colonic mucosal blood flow, the laser Doppler perfusion imager (LDPI; Perimed Inc., North Royalton, OH) with computer software was used. In anesthetized mice (n = 5, in each group) a median laparotomy was performed and the mesentery exposed. The LDPI 670-nm helium-neon laser beam was placed 12 cm above the mesentery to sequentially scan the surface of the mesentery and detect moving blood cells. In the presence of moving blood cells, the frequency shifts of the backscattered light are detected by a photodetector and processed to determine a percentage perfusion value (http://www.perimed.se). The microvascular blood flow (recorded as arbitrary units) was derived from the power spectra of backscattered laser light representing the distribution of Doppler shifts of the erythrocyte velocities.
Maximum, minimum, and mean percentage perfusion was normalized to total pixel area. After measurement of mesenteric perfusion was completed, the colonic mucosa was exposed by antimesenteric longitudinal opening of the midcolon over a length of 2 cm. After gentle removal of fecal material with a cotton tip the percentage perfusion of colonic mucosa was determined. At the end of the measurements the mice were sacrificed.
Statistical analysis
Data are reported as mean ± standard deviation (SD). Statistics were performed using SPSS 12.0 software (SPSS Inc., Chicago, IL). Analysis of variance (ANOVA) with the post hoc Bonferroni test was used for comparisons between multiple groups. In cases when there were only two groups for comparison, the two-tailed Student's t test was used. Results were considered significant at P < 0.05. Fig. 1 Body weight loss is shown as percentage change from baseline. ACE-inhibitor (ACE-I) treatment significantly reduced the loss of body weight associated with DSS-induced colitis.
* P < 0.05, * * P < 0.005, and * * * P < 0.001, ACE-I versus placebo. Error bars indicate mean ± SE 
Results
Effect of ACE-I on clinical parameters
Body weights
Body weight change (stated as percentage change from baseline body weight on day 0) is shown in Figure 1 . In agreement with other studies characterizing the time course of DSS colitis [3, 12, 13] , significant weight loss occurred toward the end of 1 week of DSS administration. However, ACE-I treatment significantly protected against this weight loss (Figure 1) . The difference between the placebo-and the ACE-I-treated groups became significant after day 5 of DSS. After 1 week, weight loss was severe in the placebo group (23.7 ± 4.2% weight loss) but this was significantly attenuated in the ACE-I group (16.6 ± 2.7%; P < 0.01, two-tailed unpaired t test).
Fecal blood
The onset of heme-positive stools corresponded closely to the development of weight loss. Mice in the ACE-I group experienced a significantly longer period before developing heme-positive stools (5.0 ± 0.7 days) than mice in the placebo group (3.5 ± 0.8 days; P < 0.02, two-tailed t test).
Effect of ACE-I on histopathology
As outlined in Table 1 , naïve control mice, as well as control mice receiving ACE-I but not DSS, showed no evidence of colitis. In mice receiving DSS, the most severe ulcerative lesions were consistently found in the distal colon, which is consistent with previous studies using the DSS model [2, 3] . In addition, lesions did not fully develop until near the end of 1 week of DSS, which is also in agreement with previous reports [2, 3, 12, 44] . Thus, in both the placebo group and the ACE-I-treated mice, histology was essentially normal at day 3 of DSS, and minor lesions had developed by day 5 (Figure 2 ). There was a trend toward more crypt disruption on day 5 in the placebo group in comparison to the ACE-I group, although this difference was not significant. However, severe ulcerative lesions rapidly developed by day 7 of DSS in the placebo group, and these changes were significantly attenuated in the ACE-I-treated mice (data reported in Table 1 , histopathology in Figure 2 ).
Effect of ACE-I on epithelial apoptosis
Although histological crypt disruption and ulcerations were not visible early in the course of the experiment, we questioned whether an increase in apoptosis preceded the development of these lesions. TUNEL staining demonstrated that, in fact, a very early and marked increase in epithelial cell apoptosis did occur in the development of colitis. Apoptosis was maximal at day 3 in placebo-treated mice receiving DSS. In contrast, ACE-I treatment reduced the apoptotic rate at day 3 by 42.5% (P < 0.0005; Figure 3 ). This marked increase in apoptosis occurred early in the course of DSS and decreased later, as epithelial ulcerative lesions developed (Figure 4) . Thus, in placebo-treated DSS mice by day 7, epithelial ulceration was so severe that essentially no normal crypts or surface epithelial cells remained. Apoptotic rates could not be accurately measured at the final time point in the placebo group due to epithelial disintegration (large numbers of apoptotic cells, however, were seen in the lumen; Figure 4 ). These results demonstrate the progression of ulcerative lesions, beginning with an early rise in apoptosis (prior to disruption of crypt architecture), leading to a subsequent loss of epithelial cells, and, finally, resulting in the severe lesions of DSS-induced colitis. In ACE-I treated mice, the rate of apoptosis was significantly reduced at day 3 (the time point with the highest apoptotic rate), although apoptosis was greater than in controls. By day 5 the apoptotic index was reduced in both DSS groups. However, the rate of apoptosis remained significantly lower in the ACE-I treated group compared to the saline-treated DSS mice (Figure 3 ). Thus, a sharp reduction in apoptosis with ACE-I treatment may well have contributed to the quantitative improvement in colitis grade by day 7.
To further validate these results, staining with Annexin V-a very early marker of apoptosis [52] -was performed on samples at day 3, the time point with the highest rate of apoptosis on TUNEL staining. Annexin V staining confirmed Fig. 3 The apoptotic index decreased significantly with ACE-inhibitor (ACE-I) treatment. Apoptotic index is quantified as number of TUNELpositive nuclei per colonic crypt unit (crypt and surface epithelium adjacent to crypt). Observers were blinded to the identity of tissue sections, and all observations were performed in duplicate. In DSS-induced colitis with placebo treatment, the maximum rate of apoptosis was seen at day 3, and apoptosis continued to be significantly elevated at day 5 (black bars). In contrast, ACE-I treatment (white bars) significantly reduced the maximum apoptotic rate at day 3 compared to placebo, although it was still higher than in controls. By day 5, apoptosis declined in both groups, but apoptosis in ACE-I-treated colons remained significantly lower than in saline-treated DSS mice. Comparisons made using ANOVA with post hoc Bonferroni test. Error bars show mean ± SE that ACE-I dramatically reduced the percentage of apoptotic epithelial cells, in contrast to placebo (Table 2) . Interestingly, although rates of cellular necrosis (assessed with propidium iodide) were very low at day 3, even at this early time point, epithelial cell necrosis was significantly lower in the ACE-I group than the placebo group (Table 2) , and cellular viability was increased with ACE-I treatment.
Effect of DSS on ACE expression ACE expression was investigated with Western immunoblotting to assess the effect the administration of DSS. Interestingly, mice receiving DSS showed significantly (P < 0.001) elevated expression of mucosal levels of ACE (0.91 ± 0.20) compared to control mice (0.27 ± 0.07). Thus, it is possible that increased ACE expression may have a role in the formation of inflammatory or apoptotic changes observed in DSS mice.
Effect of ACE-I on TNF-α expression TNF-α expression was investigated because previous work has demonstrated a reduction in TNF-α with ACE-I, with a corresponding reduction in apoptosis [22] . As expected, DSS-induced colitis treated with placebo was associated with a significant increase in TNF-α expression. However, in ACE-I-treated mice, TNF-α mRNA expression was significantly reduced at every time point in the study ( Figure 5 ). In fact, although the level of TNF-α was somewhat elevated in the ACE-I group, it was not significantly higher than that in control mice at any time point ( Figure 5 ). Thus, ACE-I achieved a significant reduction in TNF-α mRNA throughout the entire course of the study. Consistent with this finding, the mucosal protein concentration (by immunometric assay) Table 2 Apoptotic index by flow cytometry (% epithelial cells)
Note. Apoptosis was assessed by Annexin V staining, with PI (propidium iodide) to distinguish necrotic cells. Cells positive ( + ) for Annexin V only were considered apoptotic; cells negative ( − ) for both Annexin V and PI were considered viable. ACE-I treatment significantly reduced apoptosis and necrosis and enhanced cellular viability; flow cytometry was performed at day 3, when apoptotic rates were highest but very little necrosis had yet occurred. * P < 0.01, ACE-I versus placebo.
of TNF-α in ACE-I colons was reduced more than twofold compared to placebo (ACE-I, 22.4 ± 28.3 pg of TNF-α/mg total protein, versus placebo, 58.2 ± 51.0 pg/mg). This difference approached significance (P = 0.07).
Effect of ACE-I on Bcl-2 and bax expression
Bax and Bcl-2 mRNA expression were measured as these factors are also critical to the modulation of apoptosis in a number of cell types, including intestinal epithelium [43] . Results ( Figure 6 ) showed predominant expression of bax (pro-apoptotic) over bcl-2 (antiapoptotic) in naïve nonmanipulated controls (bax:bcl-2 ratio, 22.8 ± 45.2). Treatment of control mice with ACE-I resulted in increased expression of both bcl-2 and bax; however, the relative changes result in a marked increase in bcl-2 expression (bax:bcl-2 ratio, 1.72 ± 0.14), suggesting that a modulation in the expression of these factors is greatly influenced by the inhibition of ACE activity. This further suggests that the ACE-I-mediated decline in apoptosis may be due to this relative increase in bcl-2 expression. DSS treatment resulted in a shift in the * P < 0.05 and * * P < 0.01, DSS + ACE-I versus DSS + placebo expression of these apoptotic factors toward an increased expression of bax. This increase in bax was noted in both placebo-and ACE-I-treated DSS mice, and the differences were not significantly different. The most profound effect of ACE-I on DSS mice was noted at 5 days. At this time point, the largest decline in bcl-2 was seen in placebo (saline)-treated mice, whereas at 5 days in the ACE-I-treated group a significant (P < 0.05) rise in bcl-2 expression was noted ( Figure 6 ). The bax:bcl-2 ratios were essentially the same in all treatment groups at days 3 and 8 (not shown). How- ever, a significant difference in this ratio was observed at 5 days between the placebo-and the ACE-I-treated DSS mice (bax:bcl-2 ratio, 101.0 ± 77.8 vs 2.73 ± 0.87, respectively). This again suggests that the reduction in apoptosis by ACE-I may be mediated at least in part by an increased expression of bcl-2.
Effect of mucosal blood flow
Mucosal blood flow measurements of colonic tissue showed slightly lower levels in ACE-I-treated mice compared to untreated controls; however, the values were not significantly different between the two groups (0.976 ± 0.218 versus 0.760 ± 0.151, respectively; expressed as arbitrary units).
Discussion
In this study, ACE inhibition significantly reduced epithelial cell apoptosis, decreased mucosal expression of TNF-α, and attenuated the course of DSS-induced colitis in mice. Weight loss was significantly lower and heme-positive stools were reduced in ACE-I-treated mice. The histopathologic grade of colitis was also significantly lower in ACE-I-treated mice. Importantly, we found that the rate of colonic epithelial cell apoptosis, which was markedly elevated in placebo-treated DSS mice, was significantly reduced with ACE inhibition. This finding was confirmed using two independent techniques (Annexin V flow cytometry and TUNEL immunohistochemistry).
By following the development of the ulcerative lesions in this model over time, throughout the very early phases of DSS-induced colitis, we were able to demonstrate that a sharp increase in apoptosis precedes the development of severe mucosal damage. Although it has limitations, the DSS model is a very well-established, reproducible model used extensively in the study of UC [12] [13] [14] [15] [16] [17] . DSS-induced colitis resembles human UC in several important clinical and histopathologic features, including the high rates of apoptosis characteristic of UC [3, 16] . Improvements in DSSinduced colitis in our study correlated with a reduction in apoptotic rates [2, 3, 12, 13, 18] . The reduction in apoptosis by ACE-I may well have contributed to a subsequent decrease in the severity of mucosal lesions. Our data indicate that epithelial cell apoptosis is actually a very early phenomenon. The degree of apoptosis, at the first time point (day 3) in this study, correlated with the severity of colitis subsequently. These data agree with the observation in human UC patients that increasing rates of colonic epithelial apoptosis correlate with increasing severity of disease [1] .
Multiple lines of evidence now implicate ACE as a promoter of apoptosis [51] [52] [53] [54] . Small intestinal epithelial apoptosis is elevated in a mouse model of short bowel syndrome, and ACE-I reduces apoptosis in this setting [22] . Extensive studies in alveolar epithelial cells have demonstrated that ACE activity is necessary for apoptosis in these cells [20, 34, 35] . Ang II, produced by ACE, induces apoptosis of pulmonary alveolar epithelial cells in a dose-dependent manner [34] . The ACE/Ang system is highly expressed in the developing fetal cardiopulmonary system and adrenal glands, where tissue remodeling is mediated by high levels of apoptosis [21, 37] . However, we are unaware of any previous study examining the role of ACE in apoptosis in experimental colitis. Although it has been demonstrated that ACE is highly expressed in the small and large intestinal epithelium of rodents and of humans [26, 29, 49] , the functional role of this expression is uncertain. It was interesting to note that we observed a marked increase in the expression of ACE protein in the placebo-treated DSS mice.
We chose enalaprilat because of its proven antiapoptotic effect in the small bowel [22] . However, a number of other ACE inhibitors have also been shown to inhibit apoptosis in other tissues, including enalapril [32] , quinaprilat [36] , and captopril [35] , as well as other inhibitors of components of the ACE/Ang signaling cascade, such as Ang receptor blockers [30, 40] .
In addition, studies have shown that ACE upregulates TNF-α expression and that ACE-I downregulates TNF-α [22, 45, 48, 50] . Because TNF-α not only is a potent promoter of epithelial apoptosis, but also is potentially involved in the pathophysiology of the inflammatory process seen in UC, we questioned whether ACE-I would affect TNF-α expression in the DSS model. Interestingly, we found that ACE-I did significantly downregulate TNF-α mRNA expression at every time point in this study, in addition to the nearly significant twofold reduction in protein expression at 3 days. Our results suggest that ACE within the colonic mucosa is involved in downregulation of TNF-α, and this action may be involved in the mechanism by which ACE-I reduced both apoptosis and the inflammatory process. However, TNF-α is known to be controlled (at both the transcriptional and the posttranscriptional level) by a very complex network of signaling cascades, and it is likely that other factors in addition to ACE contributed to the levels of TNF-α in our study. The effect of ACE inhibition on apoptosis may involve other signaling cascades as well, such as ERK, JNK, NFκB, and others, which may affect TNF-α expression [33, 46, 47] . Further work will be necessary to more fully elucidate the mechanisms involved in ACE signaling in the colonic epithelium.
The finding that bax expression increased with DSS treatment suggests that the Bcl-2 family members could be another one of the mediators of the observed increase in epithelial cell apoptosis in this colitis model. The finding that treatment of control mice with ACE-I results in a reduction in the bax:bcl-2 ratio supports the findings of others suggesting that alterations in bax and bcl-2 expression may be one of the mechanisms which account for ACE-I-mediated decrease in apoptosis [55] . Similarly, we found a marked increase in the bax:bcl-2 ratio in 5-day DSS mice treated with saline and a significant decline in this ratio in ACE-I-treated DSS mice.
ACE-I can clearly affect the blood flow and blood pressure of these mice. In order to rule out the possibility that major alterations in mesenteric blood flow could account for the observed changes in apoptosis and colitis, Doppler blood flows were determined. We found no significant change in blood flow between naïve controls and ACE-I-treated mice, suggesting that alterations in blood flow had little to no effect on the ACE-I-associated decline in apoptosis.
Although ACE inhibition produced significant clinical and histological improvements, it is noteworthy that colitis was not completely prevented by ACE-I treatment. Furthermore, apoptosis was significantly reduced but not entirely prevented. Colitis is likely to be multifactorial, and our data indicate that ACE-I prevented some, but not all, of the pro-apoptotic and inflammatory stimuli in this model. It is important to note that our findings are supported by other investigators who have recently identified a potential benefit in blocking the rennin-Ang (RAS) pathway in inflammatory bowel disease. Wengrower et al. showed that fibrotic changes were significantly diminished in a trinitrobenzene sulfonic acid (TNBS)-induced model of colitis in rats [56] . Blockade of the RAS pathway using angiotensinogen-knockout mice also resulted in a diminution of the level of inflammation in this TNBS model [57] . In another recent study, captopril and lisinopril were used in a TNBS rat model. These investigators failed to see an improvement in the histology with lisinopril but saw improvement with captopril. Additionally, they noted a diminution of the serum levels of TNF-α [58] . While the observations made by these recent publications confirm many of the findings of our work, they do not completely address the potential mechanism by which inhibition of the RAS acts to prevent colitis. Our study supports the contention that the action of ACE-I in a rodent model of ulcerative colitis may be mediated by both a diminution of pro-inflammatory cytokines and a marked decrease in epithelial cell apoptosis.
Patients with UC suffer from a complex inflammatory disease, with a primary etiology that is probably multifactorial yet incompletely understood despite decades of research. The most effective therapies to date-short of proctocolectomy-have been based on anti-inflammatory pharmacology. The idea of targeting epithelial apoptosis and blockade of TNF-α, hence, ulceration-the sequelae of inflammation-could potentially provide a novel approach to the treatment of UC. Further, the fact that the use of ACE inhibition does not have any associated immunosuppressive side effects may allow clinicians to eventually provide this therapy in conjunction with reduced doses of immunomodulating therapies.
